Results 221 to 230 of about 106,112 (301)

Treatment Patterns and Clinical Outcomes for Patients Living with Active Giant Cell Arteritis in Canada. [PDF]

Rheumatol Ther
Makhzoum JP, Avadisian M, Liazoghli D.
europepmc   +1 more source

Analysis of the Dynamics of Clinical Parameters and Serum Angiogenic Factors in Systemic Sclerosis Patients Undergoing Tocilizumab Treatment

Experimental Dermatology, Volume 35, Issue 2, February 2026.
This study demonstrates that tocilizumab (TCZ) treatment promotes microvascular recovery in systemic sclerosis (SSc), as evidenced by increased capillary density and that this improvement in vasculopathy is closely associated with enhanced pulmonary function.
Yuichiro Segawa, Takehiro Takahashi, Takuya Takahashi, Kenta Oka, Yumi Kambayashi, Toshiya Takahashi, Yoshihide Asano   +6 more
wiley   +1 more source

Tocilizumab for the Treatment of Mevalonate Kinase Deficiency [PDF]

, 2018
Nadia Rafiq, Helen J. Lachmann, Fróði Joensen, Troels Herlin, Paul Brogan   +4 more
openalex   +1 more source

Snapshot Look at Castleman Disease

Journal of Cellular and Molecular Medicine, Volume 30, Issue 3, February 2026.
ABSTRACT Castleman disease (CD) is a rare and heterogeneous group of lymphoproliferative disorders characterised by abnormal proliferation of lymphoid tissue. First described in the 1950s, it has since been classified into two major clinical forms: unicentric CD (UCD), involving a single lymph node region and multicentric CD (MCD), which affects ...
Ciprian Jitaru, Natalia Zlampa, Delia Dima, Anca Bojan, Mihnea Zdrenghea, Laura Urian, David Kegyes, Anamaria Bancos, Maria Santa, Andrei Ivancuta, Bobe Petrushev, Madalina Nistor, Bogdan Tigu, Catalin Constantinescu, Bogdan Fetica, Maria Puiu, Mihai‐Stefan Muresan, Ciprian Tomuleasa   +17 more
wiley   +1 more source

Bispecific Antibodies: Strategies Available to Optimize Their Safe Delivery in Patients with Multiple Myeloma. [PDF]

Antibodies (Basel)
Giles HV, Kishore B.
europepmc   +1 more source

Tocilizumab provides a potential therapeutic option for the management of hyperhaemolysis syndrome in sickle cell disease: A case series and brief narrative overview of the literature

Transfusion Medicine, Volume 36, Issue 1, Page 66-71, February 2026.
Abstract Background and Objectives Hyperhaemolysis syndrome is a life‐threatening complication of transfusion, potentially triggered by macrophage activation, with limited treatment options. Tocilizumab, an anti‐IL6 monoclonal antibody, has mechanistic rationale for use and has been shown to be effective in a small number of cases.
S. Wolf, B. Singh, A. Zaidi, P. Greaves, F. Oyesanya, S. Bennett, B. Kaya, F. Barroso, P. Telfer   +8 more
wiley   +1 more source

Tocilizumab-induced psoriatic dermatitis in polyarticular juvenile idiopathic arthritis: A rare case report. [PDF]

SAGE Open Med Case Rep
Rajesh RY, Biju Seena P, Nakhutsrishvili E, Akkineni T, Ahmed AA, Suvvari TK, Thomas V, Singh T.   +7 more
europepmc   +1 more source

Giant Cell Arteritis Following Dental Procedure. [PDF]

Cureus
Jabaiah A.
europepmc   +1 more source

The effects of interleukin-6-receptor inhibition on monocytes in STEMI: a substudy of the ASSAIL-MI trial. [PDF]

EBioMedicine
Huse C, Murphy SL, Yang K, Balzer NR, Stokke MK, Anstensrud AK, Bjerkeli V, Rentz T, Jha PK, Ugland HK, Michelsen AE, Ueland T, Holm S, Tøllefsen IM, Bendz B, Kleveland O, Andersen GØ, Gullestad L, Louch WE, Woxholt S, Osnes L, Broch K, Ulas T, Aukrust P, Libby P, Halvorsen B, Dahl TB.   +26 more
europepmc   +1 more source

Effects of colchicine, interferon β, IVIG, tocilizumab and corticosteroids on COVID-19 patient survival from all presently available published clinical trials: A narrative review.

Kobra Bahrampour Juybari, Manzume Shamsi Meymandi, Hamideh Bashiri   +2 more
openalex   +2 more sources